About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(Thy1-SNCA)61Ema
transgene insertion 61, Eliezer Masliah
MGI:5435401
Summary 1 genotype
Jump to Allelic Composition Genetic Background Genotype ID
tg1
Tg(Thy1-SNCA)61Ema/0 involves: C57BL/6 * DBA/2 MGI:5435409


Genotype
MGI:5435409
tg1
Allelic
Composition
Tg(Thy1-SNCA)61Ema/0
Genetic
Background
involves: C57BL/6 * DBA/2
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Thy1-SNCA)61Ema mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
nervous system
• increased diameters, decreased number of branches, and decreased total lengths of microglia branches microglia within the caudoputamen and substatia nigra of antibiotic-treated specific pathogen-free (SPF) mice and mice rederived under germ-free conditions
• GF mice colonized with SPF gut microbiota or fed short-chain fatty acids (SCFA) exhibit increased microglia diameter in the frontal cortex, but not the cerebellum, compared with similarly treated wild-type mice
• however, SPF mice treated with antibiotics postnatally (Abx) exhibit wild-type microglia diameter whether or not they are fed SCFA
• mice rederived under germ-free conditions (GF) or fail to exhibit a reduction in microglia maturation and/or activation state unlike similarly treated wild-type mice relative to antibiotic-treated specific pathogen-free (SPF) mice
• in the caudoputamen and substatia nigra of antibiotic-treated specific pathogen-free (SPF) mice
• however, mice rederived under germ-free conditions exhibit fewer alpha synuclein aggregates; and supplementation with short chain fatty acids does not alter alpha-synuclein aggregation
• alpha-synuclein protein accumulates in synapses and neurons throughout the brain, including the neuropil of presynaptic terminals, thalamus, substantia nigra, neocortex, limbic system, hippocampus; in both pyramidal and nonpyramidal cells

behavior/neurological
• in antibiotic-treated specific pathogen-free (SPF) mice at 12-13 week and in aged mice
• GF mice colonized with SPF gut microbiota or fed short chain fatty acids exhibit as severe defects as SPF mice
• however, mice rederived under germ-free conditions exhibit similar performance to wild-type mice
• however, SPF mice treated with antibiotics postnatally (Abx) perform similar to wild-type and mice raised in germ-free conditions
• at 12-13 week, antibiotic-treated specific pathogen-free (SPF) mice require more time to cross a challenging beam and to descend a pole and take longer to remove an adhesive from the nasal bridge compared with SPF wild-type mice
• aged mice rederived under germ-free conditions (GF) require more time to cross a challenging beam and to descend a pole and take longer to remove an adhesive from the nasal bridge compared with SPF wild-type mice
• GF mice colonized with live SPF gut microbiota exhibit as severe defects as SPF mice
• GF mice fed short chain fatty acids (SCFA) exhibit impaired performance compared with controls
• however, 12-13 week old mice rederived under germ-free conditions (GF) exhibit reduced deficits in pole descent time and normal time to cross a beam or remove an adhesive
• however, SPF mice treated with antibiotics postnatally (Abx) perform similar to wild-type and mice raised in germ-free conditions
• however, treatment of short chain fatty acid fed nice with an anti-inflammatory compound minocycline improves motor function
• in both antibiotic-treated specific pathogen-free (SPF) mice and mice rederived under germ-free conditions at 12-13 week and in aged mice

digestive/alimentary system
• GF mice fed short chain fatty acids (SCFA) exhibit reduced fecal output compared with controls
• antibiotic-treated specific pathogen-free (SPF) mice exhibit reduced fecal pellet water content compared with wild-type mice
• GF mice colonized with SPF gut microbiota exhibit reduced fecal output as in SPF mice
• however, mice rederived under germ-free conditions exhibit fecal pellet water content
• however, SPF mice treated with antibodies postnatally exhibit less severe reduction in fecal output
• in both antibiotic-treated specific pathogen-free (SPF) mice at 12-13 week and in aged mice
• however, mice rederived under germ-free conditions exhibit fecal output at 12-13 week and in aged mice

growth/size/body
• in both antibiotic-treated specific pathogen-free (SPF) mice at 12-13 week and in aged mice
• however, mice rederived under germ-free conditions exhibit normal weight at 12-13 week and in aged mice

hematopoietic system
• increased diameters, decreased number of branches, and decreased total lengths of microglia branches microglia within the caudoputamen and substatia nigra of antibiotic-treated specific pathogen-free (SPF) mice and mice rederived under germ-free conditions
• GF mice colonized with SPF gut microbiota or fed short-chain fatty acids (SCFA) exhibit increased microglia diameter in the frontal cortex, but not the cerebellum, compared with similarly treated wild-type mice
• however, SPF mice treated with antibiotics postnatally (Abx) exhibit wild-type microglia diameter whether or not they are fed SCFA
• mice rederived under germ-free conditions (GF) or fail to exhibit a reduction in microglia maturation and/or activation state unlike similarly treated wild-type mice relative to antibiotic-treated specific pathogen-free (SPF) mice

immune system
• increased diameters, decreased number of branches, and decreased total lengths of microglia branches microglia within the caudoputamen and substatia nigra of antibiotic-treated specific pathogen-free (SPF) mice and mice rederived under germ-free conditions
• GF mice colonized with SPF gut microbiota or fed short-chain fatty acids (SCFA) exhibit increased microglia diameter in the frontal cortex, but not the cerebellum, compared with similarly treated wild-type mice
• however, SPF mice treated with antibiotics postnatally (Abx) exhibit wild-type microglia diameter whether or not they are fed SCFA
• mice rederived under germ-free conditions (GF) or fail to exhibit a reduction in microglia maturation and/or activation state unlike similarly treated wild-type mice relative to antibiotic-treated specific pathogen-free (SPF) mice

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
Parkinson's disease 1 DOID:0060367 OMIM:168601
J:137490





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
12/10/2024
MGI 6.24
The Jackson Laboratory